Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Net Income Loss of -$644.76 million for the year ending 2025.
- RECURSION PHARMACEUTICALS, INC. showed a decrease of -39.1% in Net Income Loss from 2024 to 2025.
- This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$18.42 million | Q2 2020: -$18.94 million | Q3 2020: -$23.87 million | Q1 2021: -$30.72 million | Q2 2021: -$43.40 million | Q3 2021: -$47.43 million | Q1 2022: -$55.98 million | Q2 2022: -$65.56 million | Q3 2022: -$60.45 million | Q1 2023: -$65.33 million | Q2 2023: -$76.73 million | Q3 2023: -$93.02 million | Q1 2024: -$91.37 million | Q2 2024: -$97.54 million | Q3 2024: -$95.84 million | Q1 2025: -$202.49 million | Q2 2025: -$171.90 million | Q3 2025: -$162.25 million.
- Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Net Income Loss has declined by 942.0%.
- Historical annual values: Fiscal year 2025: -$644.76 million | Fiscal year 2024: -$463.66 million | Fiscal year 2023: -$328.07 million | Fiscal year 2022: -$239.48 million | Fiscal year 2021: -$186.48 million | Fiscal year 2020: -$87.01 million | Fiscal year 2019: -$61.88 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: